Home＞BUSINESS
Shionogi, UMN Pharma Conclude Capital Alliance; Tie Up in Infectious Disease Field(Nov.2.2017)
Shionogi and the biotech startup UMN Pharma on October 31 announced a capital investment and business alliance agreement. Under the agreement, UMN Pharma will allocate 600,000 shares of common stock and a first issuance of convertible bonds with stock acquisition rights to Shionogi, which is expected to invest around 1.6 billion yen for the acquisition ...
(LOG IN FOR FULL STORY)
-
- Takeda in Talks with Shire after 3 Buyout Proposals Rejected Apr.20
- Industry Group Anticipates New Demand for Contract Reps after Current Phase of Downsizing by Drug Makers Apr.20
- Toho Grabs 8% Stake in NKT Cell Immunotherapy Startup Apr.19
- Astellas Sells Agensys Research Facilities to Kite Apr.19
- US Appeals Court Favors Sumitomo Dainippon in Latuda Substance Patent Suit Apr.19
- Label Revision Ordered for Keytruda with Sclerosing Cholangitis as ADR(Apr.20)
- Takeda in Talks with Shire after 3 Buyout Proposals Rejected(Apr.20)
- Industry Group Anticipates New Demand for Contract Reps after Current Phase of Downsizing by Drug Makers(Apr.20)
- Biosimilar Use Essential to Sustain Universal Health Coverage: Society President(Apr.19)
- MHLW Sees Solid Inquiry Numbers for Conditional Early Approval System: Official(Apr.19)
